Following the first commercial launch, it may still be months or even years before the medicine is approved for commercial supply to patients on a global scale. During this time, Clinigen can manage access to such medicine on an unlicensed basis.
For many reasons, a full global launch may not be part of a pharmaceutical/biotech company’s market access strategy. However, patient demand may still need to be met. Our experience in providing access to unlicensed medicines on a global scale will enable us to support the supply of medicine to territories where is it not commercially available, ensuring patients have access to the medicines they need.
Additionally, as a pharmaceutical company in our own right, we can transition the medicine from an unlicensed to commercial status by obtaining marketing authorisation on your behalf. Both options provide you with the opportunity to maximise patient access to your medicine and the value of your asset on a global scale.